Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15727MR)

This product GTTS-WQ15727MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15727MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6147MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ12386MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ1396MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ4994MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ15987MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ12663MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ6406MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW